Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Synthetic DNA/RNA Analogues Display Potent Antibiotic Activity

By BiotechDaily International staff writers
Posted on 29 Oct 2013
Image: Scanning electron microscope image of A. baumannii, with maps of its genome (outer circle) and alien-island sequences (inner circle, red) (Photo courtesy of J. Carr, [US] Centers for Disease Control; T. Gianoulis and D. Massa, Yale University).
Image: Scanning electron microscope image of A. baumannii, with maps of its genome (outer circle) and alien-island sequences (inner circle, red) (Photo courtesy of J. Carr, [US] Centers for Disease Control; T. Gianoulis and D. Massa, Yale University).
Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), which are synthetic DNA/RNA analogues that silence expression of specific genes, were found to inhibit the growth of Acinetobacter in vitro and in vivo.

Acinetobacter is frequently isolated in nosocomial infections and is especially prevalent in intensive care units with sporadic cases as well as epidemic and endemic occurrence. A. baumannii is a frequent cause of nosocomial pneumonia, especially of late-onset ventilator associated pneumonia. It can cause various other infections including skin and wound infections, bacteremia, and meningitis, while A. lwoffi is mostly responsible for the latter. A. baumannii can survive on the human skin or dry surfaces for weeks. Acinetobacter species are innately resistant to many classes of antibiotics, including penicillin, chloramphenicol, and often aminoglycosides.

Investigators at Oregon State University (Corvallis, OR, USA) sought to determine whether PPMOs targeted to essential genes in A. lwoffii and A. baumannii were active in vitro and in vivo. They evaluated PPMOs in vitro cultures using the minimum inhibitory concentration (MIC) of the drug and viability assays, and in vivo using mouse pulmonary infection models with intranasal PPMO treatment.

Results published in the October 14, 2013, online edition of the Journal of Infectious Diseases revealed that the most effective PPMO tested was (RXR)4-AcpP, which was targeted to the acpP gene. This PPMO reduced viability of A. lwoffii and A. baumannii by more than 1,000 colony-forming units per milliliter at five to eight times the MIC. Mice treated with (RXR)4-AcpP survived longer and had less inflammation and bacterial lung burden than mice treated with a scrambled-sequence PPMO or phosphate-buffered saline. Treatment could be delayed after infection and still increase survival.

“The mechanism that PPMOs use to kill bacteria is revolutionary,” said first author Dr. Bruce Geller, professor of microbiology at Oregon State University. “They can be synthesized to target almost any gene, and in that way avoid the development of antibiotic resistance and the negative impacts sometimes associated with broad-spectrum antibiotics.”

Related Links:

Oregon State University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Difference in DP103 (red) levels in a healthy person (left image) and a breast cancer patient (right image) (Photo courtesy of the National University of Singapore).

BP103 Cited as Breast Cancer Biomarker and Potential Treatment Target

Cancer researchers in Singapore have identified the DP103 oncogene in human breast cancers as a biomarker for the molecular processes that drive reappearance and metastasis of tumors following chemotherapy.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Assessing Myeloma Progression Using Calcium Isotope Analysis

Scientists are revealing how an Earth science research principle can be used in biomedical situations to predict the development of disease. The researchers evaluated a new approach to detecting bone loss in cancer patients by using calcium isotope analysis to predict whether myeloma patients are at risk for developing... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.